Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 6
1975 39
1976 83
1977 30
1978 60
1979 74
1980 66
1981 101
1982 116
1983 112
1984 144
1985 154
1986 162
1987 162
1988 165
1989 203
1990 209
1991 194
1992 211
1993 281
1994 244
1995 239
1996 233
1997 264
1998 250
1999 280
2000 298
2001 255
2002 223
2003 253
2004 243
2005 284
2006 303
2007 314
2008 356
2009 340
2010 337
2011 338
2012 317
2013 368
2014 398
2015 366
2016 368
2017 375
2018 408
2019 427
2020 464
2021 447
2022 411
2023 347
2024 416
2025 455
2026 280

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,379 results

Results by year

Filters applied: . Clear all
Page 1
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. ...These effects may be unique to low dosages of naltrexone and appear to be entir …
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multi …
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK, Schultz BG, Berlau DJ. Patten DK, et al. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
Naltrexone is a mu-opioid receptor antagonist indicated by the U.S. Food and Drug Administration for opioid and alcohol dependence. ...It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low-dose naltrexone for use i …
Naltrexone is a mu-opioid receptor antagonist indicated by the U.S. Food and Drug Administration for opioid and alcohol dependence. . …
Opioid antagonists.
Barnett V, Twycross R, Mihalyo M, Wilcock A. Barnett V, et al. J Pain Symptom Manage. 2014 Feb;47(2):341-52. doi: 10.1016/j.jpainsymman.2013.12.223. J Pain Symptom Manage. 2014. PMID: 24512968 Free article. Review. No abstract available.
Morphine/naltrexone.
Duggan ST, Scott LJ. Duggan ST, et al. CNS Drugs. 2010 Jun;24(6):527-38. doi: 10.2165/11204620-000000000-00000. CNS Drugs. 2010. PMID: 20443648 Review.
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to …
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release …
Naltrexone.
Kleber HD. Kleber HD. J Subst Abuse Treat. 1985;2(2):117-22. doi: 10.1016/0740-5472(85)90036-4. J Subst Abuse Treat. 1985. PMID: 3007777
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone …
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in Nove …
Methylnaltrexone.
Hendrikx JJ, Beijnen JH, Schellens JH. Hendrikx JJ, et al. Oncologist. 2009 Jul;14(7):679-82. doi: 10.1634/theoncologist.2009-0049. Epub 2009 Jul 15. Oncologist. 2009. PMID: 19605844 Free article. Review. No abstract available.
Extended-release intramuscular naltrexone.
Swainston Harrison T, Plosker GL, Keam SJ. Swainston Harrison T, et al. Drugs. 2006;66(13):1741-51. doi: 10.2165/00003495-200666130-00006. Drugs. 2006. PMID: 16978037 Review.
An extended-release intramuscular formulation of naltrexone that provides sustained release of the drug over a 28-day period has been developed with the aim of improving treatment adherence in patients treated with naltrexone for alcohol dependence. Biodegradable po …
An extended-release intramuscular formulation of naltrexone that provides sustained release of the drug over a 28-day period has been …
[Naltrexone].
Schifano F, Murri R, Gava R. Schifano F, et al. G Clin Med. 1989 May;70(5):379-84. G Clin Med. 1989. PMID: 2666229 Review. Italian. No abstract available.
Naltrexone: A Pan-Addiction Treatment?
Aboujaoude E, Salame WO. Aboujaoude E, et al. CNS Drugs. 2016 Aug;30(8):719-33. doi: 10.1007/s40263-016-0373-0. CNS Drugs. 2016. PMID: 27401883 Review.
Despite the very different presentations within and between both addiction categories, the data, as a whole, show consistency in favor of naltrexone's relative efficacy and safety. Given the potential benefit and good tolerability revealed in the studies, the high m …
Despite the very different presentations within and between both addiction categories, the data, as a whole, show consistency in favor of …
[Naltrexone].
San Molina L. San Molina L. Med Clin (Barc). 1987 Apr 11;88(14):556-8. Med Clin (Barc). 1987. PMID: 3586751 Spanish. No abstract available.
12,379 results
You have reached the last available page of results. Please see the User Guide for more information.